Tumor Cell Dormancy: Threat or Opportunity in the Fight Against Cancer
Preprint
- 11 October 2018
- preprint
- Published by MDPI AG in Preprints.org
Abstract
Tumor dormancy, a clinically undetectable state of cancer, makes a major contribution to the development of multidrug resistance (MDR), minimum residual disease (MRD), tumor outgrowth, cancer relapse, and metastasis. Despite its high incidence, the whole picture of dormancy-regulated molecular programs is far from clear. That is, it is unknown when and which dormant cells will resume proliferation causing late relapse, and which will remain asymptomatic and harmless to their hosts. Thus, identification of dormancy-related culprits and understanding their roles can help predict cancer prognosis and may increase the probability of a timely therapeutic intervention for the desired outcome. Here, we provide a comprehensive review of the dormancy-dictated molecular mechanisms, including an angiogenic switch, immune escape, cancer stem cells, extra cellular matrix (ECM) remodeling, metabolic reprogramming, miRNAs, epigenetic modifications, and stress-induced-p38 signaling pathways. Further, we analyze the possibility of leveraging these dormancy-related molecular cues to outmaneuver cancer, and discuss the implications of such approaches in cancer treatment.Keywords
All Related Versions
This publication has 127 references indexed in Scilit:
- IFN-γ orchestrates tumor elimination, tumor dormancy, tumor escape, and progressionJournal of Leukocyte Biology, 2018
- Combination of nanotechnology with vascular targeting agents for effective cancer therapyJournal of Cellular Physiology, 2017
- Modulating tumor hypoxia by nanomedicine for effective cancer therapyJournal of Cellular Physiology, 2017
- Tumor vascular infarction: prospects and challengesInternational Journal of Hematology, 2017
- Mer Tyrosine Kinase Regulates Disseminated Prostate Cancer Cellular DormancyJournal of Cellular Biochemistry, 2016
- SDF-1/CXCR4 promotes epithelial–mesenchymal transition and progression of colorectal cancer by activation of the Wnt/β-catenin signaling pathwayCancer Letters, 2014
- The BMP Inhibitor Coco Reactivates Breast Cancer Cells at Lung Metastatic SitesCell, 2012
- Molecular mechanisms underlying tumor dormancyCancer Letters, 2010
- Tumor dormancy due to failure of angiogenesis: role of the microenvironmentClinical & Experimental Metastasis, 2008
- nm23‐H1 reduces in vitro cell migration and the liver metastatic potential of colon cancer cells by regulating myosin light chain phosphorylationInternational Journal of Cancer, 2003